SANTA CLARA, Calif.—Twice in one week—on June 21 and then on June 25—the board of directors of Symyx Technologies has rejected a bid from Certara to acquire the firm for $5.75 per share, or about $200 million. According to Symyx, the offer does not constitute a superior offer to Accelrys' rival bid to acquire the company, even though San Diego-based Accelrys is only bidding $5 per share.
Articles
Symyx and Certara: When more money isn’t enough
Symyx board rejects larger offer from Certara for more ownership with AccelrysWritten byJeffrey Bouley
| 2 min read

To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
About the Author
This person does not yet have a bio.View Full Profile








